Manar Harmouch, MD
Family Medicine · Houston, TXNPI 1902242563
Payments from drug & device makers
Across 525 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$713
- AbbVie$666
- Lilly USA, LLC$625
- Amgen$578
- Pfizer$572
- plus $4K from 31 others
What the payments were for
- Food & beverage$7,98999%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 73 | $1,287 |
| AstraZeneca | 46 | $713 |
| AbbVie(2 entities) | 68 | $666 |
| Lilly USA, LLC | 49 | $625 |
| Amgen | 34 | $578 |
| Pfizer | 27 | $572 |
| GSK | 34 | $477 |
| Merck | 37 | $398 |
| Abbott | 18 | $327 |
| Boehringer Ingelheim | 17 | $311 |
| Astellas Pharma US Inc | 14 | $275 |
| Eisai Inc. | 16 | $238 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $183 |
| Sanofi-aventis U.S. LLC | 11 | $183 |
| Novartis | 11 | $161 |
| Dexcom, Inc. | 6 | $132 |
| Bayer | 6 | $122 |
| Shield Therapeutics Inc | 5 | $96 |
| Exact Sciences | 5 | $84 |
| Johnson & Johnson | 3 | $78 |
| Cranial Technologies, Inc | 5 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $61 |
| Teva Pharmaceuticals USA, Inc. | 4 | $49 |
| Shire North American Group Inc | 3 | $45 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Genentech USA, Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| IBSA Pharma Inc. | 2 | $24 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$8,034 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 128 | $208,774 |
| FarxigaDapagliflozin Propanediol | 122 | $103,529 |
| EliquisApixaban | 50 | $72,263 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $63,469 |
| MounjaroTirzepatide | 26 | $46,756 |
| ProliaDenosumab | 20 | $33,753 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $22,187 |
| JardianceEmpagliflozin | 21 | $21,921 |
| TradjentaLinagliptin | 17 | $21,508 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $16,562 |
| Nurtec OdtRimegepant Sulfate | 11 | $15,742 |
| EntrestoSacubitril/Valsartan | 17 | $14,254 |
| XareltoRivaroxaban | 13 | $13,485 |
| TrulicityDulaglutide | 14 | $12,890 |
| LinzessLinaclotide | 12 | $12,881 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,287 | $208,774128 claims |
| AstraZenecaFarxiga | $713 | $103,529122 claims |
| PfizerEliquis, Nurtec Odt, Prempro | $572 | $90,92273 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $477 | $68,66881 claims |
| Lilly USA, LLCMounjaro, Trulicity | $625 | $59,64640 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $311 | $48,43951 claims |
| AmgenProlia | $578 | $33,75320 claims |
| AbbVieLinzess, Creon, Synthroid | $666 | $26,22084 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $183 | $22,18715 claims |
| NovartisEntresto | $161 | $14,25417 claims |
| Johnson & JohnsonXarelto | $78 | $13,48513 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $35 | $8,90017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Houston
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
- Bonnie ColvilleHouston$19.6M
- Oscar de ValleHouston$12.8M
- van TranHouston$11M
- Joe PouzarHouston$10.7M
- Aalia Al-BarwaniHouston$6.8M
- Terence ChangHouston$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.